Glycoprotein IIb/IIIa antagonists

Glycoprotein IIb/IIIa antagonists

Glycoprotein IIb/IIIa antagonists are classified as antiplatelet agents. The antagonists were developed when medical practitioners gained knowledge that there exists a condition caused by lack of the GpIIb/IIIa. The condition is referred to as Glanzmann’s thrombasthenia. There are several glycoprotein IIb/IIIa antagonists that exist which include orbofiban, eptifibatide, tirofiban, abciximab, and roxifibian. Glycoprotein IIb/IIIa antagonists are often used in percutaneous coronary intervention involving a surgery involving the widening of an obstructed blood vessel with or without the placement of ascent (Han, Guo, Zheng, Zang, Su, Wang, … & Jiang, 2015).

They are thus used to prevent platelets from coming together and forming a blood clot. They do so by stopping the GpIIb/IIIa receptor on the surface of the platelets in a person’s body. It means that the glycoprotein IIb/IIIa antagonists come in between the multiplication of the platelets in the body. These antagonists can also be used in the treatment of sensitive and recognizable pattern of symptoms regarding the arteries and veins of the heart. Here, there is no percutaneous intervention but depends on the risk involved and the severity of the illness in a patient. High-risk patients receive a GP IIb/IIIa antagonist (Han, Guo, Zheng, Zang, Su, Wang, … & Jiang, 2015).

The smaller agents such as eptifibatide and tirofiban can be administered 1 to 2 days before and continued with the procedure. Abciximab is used only in PCI. The antagonists should be administered to a patient down through a needle which is inserted into his or her vein (Taslakian, Sebaaly & Al-Kutoubi, 2016). The reason behind this is that there is high death rate associated with the administration of the antagonists orally hence oral administration is discouraged. However, a large dose of these agents is administered intracoronary which may be a remedy to the patients suffering from a high thrombotic burden (Taslakian, Sebaaly & Al-Kutoubi, 2016)

References

Han, Y., Guo, J., Zheng, Y., Zang, H., Su, X., Wang, Y., … & Jiang, D. (2015). Bivalirudin vs. heparin with or without tirofiban during the primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. Jama, 313(13), 1336-1346.

Taslakian, B., Sebaaly, M. G., & Al-Kutoubi, A. (2016). Patient evaluation and preparation in vascular and interventional radiology: what every interventional radiologist should know (part 2: patient preparation and medications). Cardiovascular and interventional radiology, 39(4), 489-499.

 

Place this order or similar order and get an amazing discount. USE Discount code “GWEXDDSRGCF10” for 10% discount